Ideaya Biosciences Partners with Hengrui Pharma for Novel Cancer Treatment

Exclusive Global License Agreement for SHR-4849 Rational Combination Opportunities in Precision Medicine Oncology IDEAYA Biosciences, Inc. has recently announced an exclusive global license agreement for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate. This innovative program targets DLL3, which is highly expressed in Small Cell Lung Cancer (SCLC) and Neuroendocrine Tumors (NETs). With DLL3…

Read More

Unleash Your Investing Superpowers with VFMV: The Low Volatility ETF That’s Solid, But Not Quite Super

VFMV: A Closer Look at Low-Volatility ETFs Introduction When it comes to investing, finding a balance between risk and return is crucial. One strategy that has gained popularity in recent years is investing in low-volatility stocks through Exchange-Traded Funds (ETFs). These ETFs aim to provide exposure to a well-diversified basket of stocks with lower levels…

Read More

Mark Your Calendars: Don’t Miss the January 13, 2025 Deadline for Kessler Topaz Meltzer Check LLP’s Securities Fraud Class Action Lawsuit Against PACS Group Inc.

Welcome to our Blog Post! Investors Warned of Securities Class Action Lawsuit Against PACS Group, Inc. RADNOR, Pa., Dec. 28, 2024 (GLOBE NEWSWIRE) — The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District…

Read More

Unlocking the Secrets of Myers Industries: A Bargain Buy or a Cosmic Waiting Game?

Investing in Myers Industries: A Patient Investor’s Dream The Road to Recovery Myers Industries’ recent struggles have been well-documented, with lowered EPS guidance causing concern among investors. However, the company’s recent acquisition of Signature Systems presents a glimmer of hope, with expected synergies and profitability improvements on the horizon. A Plan for Success Myers Industries’…

Read More